血管内皮抑制素联合NP方案治疗晚期复发、转移性乳腺癌的疗效观察

Observations on the efficacy of chemotherapy by Endostatin combined with NP regimen on recurrent metastatic breast cancer

目的观察血管内皮抑制素(恩度)联合NP方案治疗晚期复发、转移性乳腺癌的近期疗效及毒副作用。方法经病理证实的晚期复发、转移性乳腺癌患者15例,既往均接受多程化疗及内分泌治疗,现接受恩度联合NP方案化疗。化疗1周期后评价毒副反应,化疗2周期后评价化疗效果。结果 13例可评价疗效的病例中获得完全缓解(CR)1例、部分缓解(PR)3例、稳定(SD)7例和疾病进展(PD)2例,客观有效率30.1%,疾病控制率84.6%。全组患者无严重不良反应。结论在晚期乳腺癌患者中,一线治疗失败后改用恩度联合NP方案化疗后能改善患者生活质量,延长生存期,安全性好毒副反应低,值得临床进一步深入观察。

Objective To observe the efficacy of and side effects of Endostatin combined with NP program in recurrent metastatic breast cancer.Methods Fifteen cases of recurrent metastatic breast cancer who had received chemotherapy and Endocrine treatment now received Endostatin combined with NP regimen.The curative effect and the side effect were evaluated after one week,and the effectiveness of medicinal treatment was evaluated after two weeks.Results Thirteen cases were eventually evaluated.There was 1 CR case,3 PR cases,7 SD cases,2 PD cases,and the objective response rate（RR） and disease control rate（DCR） were 30.1% and 84.6% respectively.The whole group without serious adverse events.Conclusion For recurrent metastatic breast cancer,after the failure of front-line chemotherapy,we adopted Endostatin combined with NP regimen to improve their life quality,and prolong survival,this regimen has more safety,low toxic and side-effects.This method is worth,in short,popularizing clinically.